Bimekizumab Biosimilar - Research Grade

Human

IL17A

>1mg/ml

IgG1 - kappa

CHO Cells

Secukinumab Biosimilar - Research Grade (ICH4033), Ixekizumab Biosimilar - Research Grade (ICH5165), Xeligekimab Biosimilar - Research Grade (ICH5289), Afasevikumab Biosimilar - Research Grade (ICH5330), Gumokimab Biosimilar - Research Grade (ICH5586), Netakimab Biosimilar - Research Grade (ICH5709), Perakizumab Biosimilar - Research Grade (ICH5769), Roconkibart Biosimilar - Research Grade (ICH5829), Vunakizumab Biosimilar - Research Grade (ICH5995)

https://www.imgt.org/mAb-DB/

ICH3002

Q16552

Blue ice

ICH5403 is a research-grade biosimilar of bimekizumab, supplied as an unconjugated, non-therapeutic analog of the originator antibody for research use only. It is built to reproduce the antigen-binding characteristics of bimekizumab, a humanized IgG1-kappa monoclonal antibody, and is intended as a reference and control reagent rather than a clinical drug. The originator, bimekizumab, is notable for its dual specificity: it selectively neutralizes both interleukin-17A (IL-17A, UniProt Q16552) and interleukin-17F, distinguishing it from agents that target IL-17A alone or the shared IL-17 receptor. This biosimilar is offered for functional and in-vitro applications such as characterizing IL-17A binding and neutralization, benchmarking against other anti-IL-17 reagents, and serving as an isotype-matched control in assay development. It is produced to research-grade specifications with low endotoxin content and is available in bulk quantities (mg to g scale) suitable for larger studies. As a human-directed biosimilar, it is not positioned as a murine in-vivo depletion or blockade tool. Users should confirm that the reagent's binding profile matches their intended IL-17A (and, where relevant, IL-17F) application. Guidance for ichorbio to review. Interleukin-17A (IL-17A; UniProt Q16552) is a homodimeric pro-inflammatory cytokine and the signature effector of T-helper 17 (Th17) cells, also produced by gamma-delta T cells, innate lymphoid cells, and neutrophils. It signals through the IL-17RA/IL-17RC receptor complex to activate NF-kappa-B and MAPK pathways, driving expression of chemokines, cytokines, and antimicrobial peptides. IL-17A promotes neutrophil recruitment and supports epithelial barrier defense against extracellular bacteria and fungi. IL-17A can form heterodimers with the closely related IL-17F, and both cytokines contribute to chronic inflammatory and autoimmune conditions such as psoriasis, psoriatic arthritis, and axial spondyloarthritis. Bimekizumab is distinctive in neutralizing both IL-17A and IL-17F, providing broader suppression of IL-17-driven inflammation than IL-17A-selective agents. This dual pathway makes IL-17A a central node in barrier immunity and inflammatory disease research.

IL-17, Cytotoxic T-lymphocyte-associated antigen 8, CTLA-8, Interleukin-17A

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks